ГРИФОЛЬС ЛУКАС Виктор (ES),ГРИФОЛЬС РОУРА Виктор (ES)
申请号：
RU2013110503/14
公开号：
RU2013110503A
申请日:
2013.03.11
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. A method for treating cholesterol-related disorders, comprising: applying a first treatment regimen comprising two or more plasmapheresis sessions in a patient having a pathological level of total cholesterol, a pathological level of LDL and / or pathological level of HDL, measured before treatment, where the first the treatment regimen lowers the level of LDL in patients with a pathological level of LDL and / or increases the level of HDL in patients with a pathological level of HDL every other session of the first treatment regimen supporting a new, lower level of total cholesterol, lower LDL and / or higher level LPVP.2. The method according to claim 1, where each subsequent session of the first treatment regimen is carried out after about 2 to about 4 days after the previous session. The method according to claim 1, where each subsequent session of the first treatment regimen is carried out from about 5 to about 9 days after the previous session. The method according to claim 1, where each subsequent session of the first treatment regimen is carried out after about 10 to about 14 days after the previous session. The method of claim 1, further comprising administering at least one statin to the patient before, during, and / or after the first treatment regimen. The method of claim 1, wherein each session of the first treatment regimen comprises a low volume plasmapheresis, wherein less than about 1000 ml of blood is treated. The method of claim 1, wherein the first treatment regimen lowers LDL levels in patients having a pathological LDL level before the first treatment regimen by about 5 mg / dl to about 45 mg / dl. The method according to claim 7, where the first treatment regimen reduces the level of LDL in patients with a pathological level of LDL before the first1. Способ лечения нарушений, связанных с уровнем холестерина, включающий:применение первой схемы лечения, включающей два или более сеансов плазмафереза, у пациента, имеющего патологический уровень
